The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". You should consider whether you understand how CFDs work and can afford the risks. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. The material provided on this website is for information purposes only and should not be understood as an investment advice. AbbVie product revenues by quarter and year since FY20. Please. Their ABBV share price forecasts range from $140.00 to $200.00. View which stocks are hot on social media with MarketBeat's trending stocks report. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. The median estimate represents a +5.72% increase from the last price of 156.07. An investment in AbbVie is not without risk, but my contention is that this Pharma is in good hands - CEO Gonzalez has made few mistakes during his near-decade in charge - and will emerge from the Humira LOE a stronger and more diverse company. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. In-depth profiles and analysis for 20,000 public companies. Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. These are Immunology, Oncology, Neurology, Virology and Eye Care. Payout ratios above 75% are not desirable because they may not be sustainable. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. AbbVie is a leader in ESG and sustainability. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. It now expects full-year profit in the range of $13.92-$14.12 a share. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets. Projections are based on making fundamental and technical studies of the ABBV stock price performance. Wallet Investor suggested that the price could hit $300.386 in June 2027. What other stocks do shareholders of AbbVie own? MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. If you have an ad-blocker enabled you may be blocked from proceeding. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . Only 0.08% of the stock of AbbVie is held by insiders. AbbVie could be the biggest global Pharma by revenue generation in 2028. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. About the AbbVie, Inc. stock forecast. AbbVie has been increasing its dividend for 51 years. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. For the next nine years, the forecast is for Revenue to grow by 3.57%. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. As such I have downgraded my own growth expectations in the forecasting table above, reducing annual growth from 7.5%, to just 2.5%, after forecasting for $5bn revenues in FY22 - down 7.5% year-on-year. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. AbbVie has a P/B Ratio of 15.97. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. View the best growth stocks for 2023 here. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). AbbVie made the bold decision to take on a heavy debt load and bid for Allergan, with the deal being completed in 2020. If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. I do much more than just articles at Haggerston BioHealth: Members get access to model portfolios, regular updates, a chat room, and more. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. It is important to do your own research, and remember that your decision to trade depends on your attitude to risk, your expertise in the market, the spread of your investment portfolio and how comfortable you feel about losing money. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. AbbVie product revenue forecasts to 2030. Receive regular, detailed analysis focused on biotech and healthcare stocks. Skyrizi - which inhibits the activities of IL-23 - a naturally occurring cytokine that is involved in inflammatory and immune responses - and Rinvoq - a member of the janus kinase inhibitor drug class - fit this profile. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. ABBV has several positive factors pushing its price performance. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. American Consumer News, LLC dba MarketBeat 2010-2023. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska druba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacuticos S.A. de C.V., AbbVie Farmacutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S. r.l., AbbVie Investments Limited, AbbVie Investments S. r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementr GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. The dividend payout ratio is 89.56%. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. AbbVie projected sales - immunology (my forecasts and assumptions). Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. The official website for the company is www.abbvie.com. Export data to Excel for your own analysis. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. AbbVie has been working hard to ensure the 2 drugs it has developed to replace Humira - Skyrizi, which inhibits the pro-inflammatory cytokine IL23, and Rinvoq, a Janus Kinase (enzymes involved in immune cell function) inhibitor - are winning approvals and growing sales in Humira's markets. This suggests a possible upside of 3.2% from the stock's current price. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. Receive regular, detailed analysis focused on biotech and healthcare stocks. It . According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. See what's happening in the market right now with MarketBeat's real-time news feed. There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. AbbVie Stock Forecast 2023 $165.00 In the last five quarters, AbbVie's Price Target has risen from $122.84 to $162.12 - a 31.98% increase. Excluding items, AbbVie earned $3.31 per share, beating estimates of $3.29 . 326 E 8th St #105, Sioux Falls, SD 57103 American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. After 2022 Humira's row is shaded yellow to signify patent expiry. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. The difference between trading assets and CFDs. The drug is now approved in severe Rheumatoid Arthritis, active Psoriatic Arthritis, moderate to severe Atopic Dermatitis, Ulcerative Colitis, active Ankylosing Spondylitis, with Crohn's Disease the next approval on the list. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 100.12. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. AbbVie discounted cash flow analysis. If you have an ad-blocker enabled you may be blocked from proceeding. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. The Abbvie stock forecast for 2025 had the price at $259.018. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. As we can see the immunology division consists of only 3 assets yet by my calculation, will likely account for 50% of AbbVie's revenues in 2022 (to calculate 2022 sales revenues by product, since we do not yet have final figures, I have used 9m 2022 figures and assumed Q4 revenues will be the average of the previous 3 quarters). Any company is likely to struggle if sales of its best-selling asset begin to decline by ~20% per annum, which is traditionally the rate at which patent expired drugs' sales slip, but when the drug in question accounts for >35% of a company's sales, as Humira does, the situation becomes even more serious. Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. Refer to our. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. Although investing in AbbVie isn't riskless, it is advisable based on what we know about the company. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! Let's begin our analysis with the immunology division. Is this happening to you frequently? As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. I have downgraded my forecasts to 2016 accordingly however to 2% annual growth. I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. Only you can design whether Abbvie stock is the right investment for you. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. All times are ET. Identify stocks that meet your criteria using seven unique stock screeners. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. (my tables). I have no business relationship with any company whose stock is mentioned in this article. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. If you rely on the information on this page then you do so entirely on your own risk. (6.33% Upside) Based on 15 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". Over the years, AbbView Inc. has made numerous acquisitions. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. On average, analysts rate AbbVie stock as a buy. View institutional ownership trends. Build a CFD portfolio with your favourite companies. That same month, the FDA extended the review period for Skyrizi (risankizumab), a treatment drug for moderate to severe Crohns disease in patients aged 16 and older. Payout ratios above 75% are not desirable because they may not be sustainable. The Abbvie stock forecast for 2025 had the price at $259.018. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . 8.05% Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. CFDs are complex leveraged instruments and come with a high risk of losing money. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. The average Abbvie stock price prediction forecasts a potential upside of 7.07% from the current ABBV share price of $155.27. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. How do I arrive at my share price target? Nevertheless, AbbVie is clearly under huge pressure to protect its dominance in the immunology markets, and the signs are it has been able to do just that thanks to the launches of 2 new drugs - Skyrizi and Rinvoq. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. All Rights Reserved. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. What is AbbVie's stock price forecast for 2023? One of the few pain points AbbVie experienced during a year of portfolio wide growth in 2022 was the decline in the revenue contribution from Imbruvica, approved to treat various types of lymphoma. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. Factset: FactSet Research Systems Inc.2019. Price target. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. I am using a weighted average cost of capital of ~10%, which is broadly consistent with the figure I use when modelling for the other 7 members of what I term the "Big 8" US Pharmas - Johnson & Johnson, Eli Lilly, Pfizer, Merck & Co (MRK), Bristol Myers Squibb, Amgen, and Gilead Sciences (GILD) - which helps prove the accuracy of the calculation. It is generally accepted however that 2023 will see the entrants into the US market of several generic versions of Humira - which works by inhibiting Tumor Necrosis Factor ("TNF"), an inflammation causing protein - from the likes of Viatris (VTRS), Organon (OGN), Pfizer (PFE), Amgen (AMGN), and several more companies involved in the development and sale of generic or biosimilar drugs. What is a Good Dividend Yield? The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. Note that analysts ABBV stock forecasts can be wrong. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. As we can see, AbbVie is likely to generate some impressive cash flow based on its operating margins, which begin at 32%. Compare Top Brokerages Here. As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Nineteen analysts predict that AbbVie's share price will increase in the coming year, reaching $165.00. PEG Ratios above 1 indicate that a company could be overvalued. Neuroscience looks highly promising too, and aesthetics capable of driving some respectable growth driven by old stager Botox. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030.
How To Get A Reservation At Nobu Malibu,
Francis Chukwudebelu Age,
Accident 302 Windham Today,
Articles A